Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
株式のランク #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
株価
$193.62
時価総額
$150.08B
変化(1日)
2.76%
変化(1年)
184.69%
GB
取引 AstraZeneca PLC (AZN)

カテゴリー

AstraZeneca PLC(AZN)のP/S比率
April 2026 時点のP/S比率 TTM: 5.08
AstraZeneca PLC の最新の財務報告および株価によると、現在のP/S比率(TTM)は 5.08 です。2023 年末時点でのP/S比率は 4.52 でした。
AstraZeneca PLC の P/S 比率の履歴(2000 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 5.08 32.53%
2024 3.83 -15.26%
2023 4.52 -4.59%
2022 4.74 5.68%
2021 4.49 0.10%
2020 4.48 -16.24%
2019 5.35 18.49%
2018 4.52 20.97%
2017 3.73 12.88%
2016 3.31 -7.94%
2015 3.59 3.88%
2014 3.46 24.71%
2013 2.77 31.79%
2012 2.10 8.57%
2011 1.94 -1.43%
2010 1.97 -2.42%
2009 2.02 4.18%
2008 1.93 -11.54%
2007 2.19 -27.51%
2006 3.02 -13.01%
2005 3.47 28.75%
2004 2.69 -37.86%
2003 4.33 24.90%
2002 3.47 3.25%
2001 3.36 -31.80%
2000 4.93 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
13.33 162.67%
US
6.25 23.21%
US
6.29 23.85%
US
5.14 1.33%
CH
4.58 -9.86%
US